Baillie Gifford Funds > Baillie Gifford Funds
Baillie Gifford Health Innovation Equities Fund
$21.36M
Avg Monthly Net Assets
$16.00M
Total Assets
$38K
Total Liabilities
$15.97M
Net Assets
Baillie Gifford Health Innovation Equities Fund is a Mutual Fund in Baillie Gifford Funds
from Baillie Gifford Funds,
based in
United Kingdom of Great Britain And Northern Ireland.
The fund has two share classes
and monthly net assets of $21.36M.
On August 20th, 2024 it reported 40 holdings, the largest
being Alnylam Pharmaceuticals Inc (7.1%), Moderna Inc (7.0%) and Argenx SE (6.4%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Ticker | Monthly Returns (2 years) |
|---|---|---|---|
| Class K | C000233009 | BGHDX | |
| Institutional Class | C000233010 | BGHBX |
Holdings
From latest NPORT-P, filed August 20th, 2024 for period ending June 28th, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| 10X Genomics Inc | Long | Equity-common | US | $134K | 7K | 0.84 |
| Alector Inc | Long | Equity-common | US | $60K | 13K | 0.37 |
| ALK-Abello A/S | Long | Equity-common | DK | $877K | 40K | 5.49 |
| Alnylam Pharmaceuticals Inc | Long | Equity-common | US | $1M | 5K | 7.06 |
| Ambu A/S | Long | Equity-common | DK | $837K | 44K | 5.25 |
| Argenx SE | Long | Equity-common | NL | $1M | 2K | 6.36 |
| Ascendis Pharma A/S | Long | Equity-common | DK | $498K | 4K | 3.12 |
| BioNTech SE | Long | Equity-common | DE | $214K | 3K | 1.34 |
| Denali Therapeutics Inc | Long | Equity-common | US | $298K | 13K | 1.87 |
| Dexcom Inc | Long | Equity-common | US | $782K | 7K | 4.90 |
| Doximity Inc | Long | Equity-common | US | $550K | 20K | 3.44 |
| Edwards Lifesciences Corp | Long | Equity-common | US | $771K | 8K | 4.83 |
| Exact Sciences Corp | Long | Equity-common | US | $493K | 12K | 3.09 |
| Exscientia Plc | Long | Equity-common | GB | $146K | 29K | 0.92 |
| Genmab A/S | Long | Equity-common | DK | $763K | 3K | 4.78 |
| GRAIL Inc | Long | Equity-common | US | $12K | 781 | 0.08 |
| Health Catalyst Inc | Long | Equity-common | US | $132K | 21K | 0.83 |
| Illumina Inc | Long | Equity-common | US | $477K | 5K | 2.99 |
| Inspire Medical Systems Inc | Long | Equity-common | US | $122K | 909 | 0.76 |
| Insulet Corp | Long | Equity-common | US | $565K | 3K | 3.54 |
| Ionis Pharmaceuticals Inc | Long | Equity-common | US | $633K | 13K | 3.96 |
| Lyell Immunopharma Inc | Long | Equity-common | US | $35K | 24K | 0.22 |
| M3 Inc | Long | Equity-common | JP | $273K | 29K | 1.71 |
| Moderna Inc | Long | Equity-common | US | $1M | 9K | 6.95 |
| Recursion Pharmaceuticals Inc | Long | Equity-common | US | $138K | 18K | 0.87 |
| Relay Therapeutics Inc | Long | Equity-common | US | $92K | 14K | 0.57 |
| ResMed Inc | Long | Equity-common | US | $509K | 3K | 3.19 |
| Sage Therapeutics Inc | Long | Equity-common | US | $30K | 3K | 0.19 |
| Sana Biotechnology Inc | Long | Equity-common | US | $29K | 5K | 0.18 |
| Sartorius AG | Long | Equity-preferred | DE | $501K | 2K | 3.14 |
| Schott Pharma AG & Co KGaA | Long | Equity-common | DE | $204K | 6K | 1.28 |
| STAAR Surgical Co | Long | Equity-common | US | $345K | 7K | 2.16 |
| Twist Bioscience Corp | Long | Equity-common | US | $275K | 6K | 1.72 |
| Veeva Systems Inc | Long | Equity-common | US | $476K | 3K | 2.98 |
| Vertex Pharmaceuticals Inc | Long | Equity-common | US | $442K | 943 | 2.77 |
| Vir Biotechnology Inc | Long | Equity-common | US | $51K | 6K | 0.32 |
| Wuxi Biologics Cayman Inc | Long | Equity-common | CN | $167K | 114K | 1.05 |
| Zai Lab Ltd | Long | Equity-common | CN | $83K | 49K | 0.52 |
| Zealand Pharma A/S | Long | Equity-common | DK | $221K | 2K | 1.38 |
| ZEALAND PHARMA A/S - TEMP LINE | Long | Equity-common | DK | $169K | 1K | 1.06 |
Address
Baillie Gifford Funds
CALTON SQUARE, ONE GREENSIDE ROW
EDINBURGH
EH1 3AN
United Kingdom of Great Britain And Northern Ireland
Websites
Directors
Pamela M. J. Cox
Howard W. Chin
Robert E. Rigsby
John Kavanaugh
David W. Salter
Donald P. Sullivan
Transfer Agents
BNY Mellon Investment Servicing (US) Inc.
Pricing Services
Intercontinental Exchange, Inc.
Custodians
The Bank of New York Mellon SA/NV (Germany)
Citibanamex Afore, S.A. de C.V.
Euroclear Bank SA/NV (Belgium)
BANCO CITIBANK S A
Standard Chartered Bank, Jakarta Branch
The Bank of New York Mellon, SA/NV (Italy)
Mizuho Bank, Ltd.
Skandinaviska Enskilda Banken AB, Oslo Branch
Standard Chartered Bank, Philippines Branch
Standard Chartered Bank (Singapore) Limited
Standard Chartered Bank Malaysia Berhad
Skandinaviska Enskilda Banken AB, Helsinki Branch
The Bank of New York Mellon, SA/NV (Netherlands)
Bank Polska Kasa Opieki S.A.
CIBC Mellon Trust Company (Canada)
Skandinaviska Enskilda Banken AB, Stockholm
HSBC HK BOND CONNECT
CACEIS BANK SPAIN S.A.
Banque Nationale de Belgique SA/NV
THE STANDARD BANK OF SOUTH AFRICA
The Hongkong and Shanghai Banking Corporation (Hong Kong)
Citibank Europe PLC (Greece)
The Bank of New York Mellon
The Bank of New York Mellon (Ireland)
Skandinaviska Enskilda Banken AB, Copenhagen Branch
Citibank del Peru S.A.
Credit Suisse (Switzerland) Ltd.
Citibank Europe Plc, Sucursal em Portugal
The Hongkong and Shanghai Banking Corporation (Thailand)
The Bank of New York Mellon (United Kingdom)
PT Deutsche Sekuritas Indonesia
The Hongkong and Shanghai Banking Corporation, Vietnam
Deutsche Investor Services Private Limited
HSBC NOMINEES (NEW ZEALAND) LIMITED
Deutsche Securities Korea Co.
Euroclear France
UniCredit Bank Austria AG
Euroclear SA/NV
Bank Hapoalim B.M.
HSBC Bank Australia Limited
Deutsche Bank A.S. (Turkey)
Aberdeen Euro Vallalati Kotveny Alapok Alapja
HSBC Bank (Taiwan) Limited
Shareholder Servicing Agents
The Bank of New York Mellon
Admins
The Bank of New York Mellon
Brokers
Joh. Berenberg, Gossler & Co. KG
BOFA SECURITIES, INC.
EUROMOBILIARE ADVISORY SIM S.P.A.
Peel Hunt LLP
SAMSUNG SECURITIES (AMERICA), INC.
UBS Securities LLC
BNP PARIBAS SECURITIES CORP.
J.P. Morgan Securities LLC
HEMBLA AB
JEFFERIES LLC